SCHEMBL13184792

SCHEMBL13184792

CCNc1c(C(=O)Nc2cc(C(=O)NC3CC3)ccc2C)cnn1-c1ccccc1

nearest known ligand 0.78

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 19/20 0.78
MAPK11 Q15759 4/20 0.74
MAPK13 O15264 1/20 0.55
MAPK12 P53778 1/20 0.55
RAB9A P51151 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13548227 0.90 MAPK14 (0.78) MAPK14MAPK11MAPK13MAPK12RAB9A
SCHEMBL13548226 0.88 MAPK14 (0.71) MAPK14MAPK11MAPK13MAPK12
SCHEMBL14097086 0.88 MAPK14 (0.74) MAPK14MAPK11MAPK13MAPK12RAB9A
SCHEMBL3519858 0.87 MAPK14 (0.82) MAPK14MAPK11MAPK13MAPK12RAB9A
SCHEMBL13548223 0.85 MAPK14 (0.79) MAPK14MAPK11MAPK13MAPK12RAB9A
SCHEMBL13548212 0.85 MAPK14 (1.00) MAPK14MAPK11MAPK13MAPK12RAB9A
SCHEMBL14097094 0.83 MAPK14 (0.73) MAPK14MAPK11MAPK13MAPK12RAB9A
SCHEMBL14097095 0.83 MAPK14 (0.75) MAPK14MAPK11MAPK13MAPK12RAB9A
SCHEMBL14097099 0.82 MAPK14 (0.83) MAPK14MAPK11
SCHEMBL16576339 0.78 MAPK14 (0.63) MAPK14MAPK11MAPK13MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1618092-B1 ARYL-SUBSTITUTED PYRAZOLE-AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2010-09-22 EP disclosed
US-20100016320-A1 ARYL-SUBSTITUTED PYRAZOLE-AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-01-21 US disclosed
US-20100016320-A1 ARYL-SUBSTITUTED PYRAZOLE-AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-01-21 US disclosed
EP-2133348-A1 Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors Bristol-Myers Squibb Company (US) 2009-12-16 EP disclosed
US-7605273-B2 Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2009-10-20 US disclosed
US-7605273-B2 Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2009-10-20 US disclosed
US-20080275092-A1 ARYL-SUBSTITUTED PYRAZOLE-AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2008-11-06 US disclosed
US-20080275092-A1 ARYL-SUBSTITUTED PYRAZOLE-AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2008-11-06 US disclosed
US-7396935-B2 Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2008-07-08 US disclosed
US-7396935-B2 Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2008-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275092-A1 ARYL-SUBSTITUTED PYRAZOLE-AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS MAPK6, CDK6, GRK6 MAPK14 62/4885MAPK11 92/4885MAPK13 83/4885
US-20100016320-A1 ARYL-SUBSTITUTED PYRAZOLE-AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS MAPK6, CDK6, GRK6 MAPK14 62/4885MAPK11 92/4885MAPK13 83/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.